<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83866">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01763749</url>
  </required_header>
  <id_info>
    <org_study_id>CLO_1201</org_study_id>
    <nct_id>NCT01763749</nct_id>
  </id_info>
  <brief_title>Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin</brief_title>
  <official_title>Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin in Korean Patients With Coronary Artery Disease (a Single-center, Randomized, Open-label Clinical Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul St. Mary's Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Aim of this study is to prove non-inferiority of Closone to the Combination treatment of
      Plavix with Astrix.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in P2Y12% inhibition at week 4</measure>
    <time_frame>Baseline, week 4</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PRU at week 4</measure>
    <time_frame>Baseline, week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>PRU : VerifyNow P2Y12 reaction unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ARU at week 4</measure>
    <time_frame>Baseline, week 4</time_frame>
    <safety_issue>No</safety_issue>
    <description>ARU : VerifyNow Aspirin Reaction Unit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Closone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75mg/100mg per day, 4weeks, PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Plavix with Astrix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Plavix 75mg with Astrix 100mg, 4weeks, PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Closone</intervention_name>
    <description>Closone 75mg/100mg, 4weeks, PO</description>
    <arm_group_label>Closone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plavix with Astrix</intervention_name>
    <description>Plavix 75mg with Astrix 100mg, 4weeks, PO</description>
    <arm_group_label>Plavix with Astrix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects under condition after Post-Percutaneous Coronary Artery Intervention over
             twelve months

          -  20~85 years old

          -  Willing to adhere to protocol requirements and sign a informed consent form

        Exclusion Criteria:

          -  Subject who did not undergo or failed Stent Implantation

          -  Subjects who took an anti-coagulant, anti-thrombotic regularly before the study, or
             plan to have continuous treatment during the study

          -  Subjects with a history of hypersensitivity to Clopidogrel, Aspirin

          -  Subjects with uncontrolled severe hypertension

          -  Subjects with high risk of hemorrhage like blood coagulation disorders

             :gastrointestinal bleeding, gross hematuria, intraocular bleeding, hemorrhagic
             stroke, intracranial hemorrhage

          -  Subjects with intractable arrhythmia, intracranial hemorrhage

          -  Subjects with Severe cardiomyopathy (New York Heart Association(NYHA) Class â…£)

          -  Subjects with Severe hepatopathy(AST and ALT &gt; 10 times the upper limit of normal)

          -  Subjects who are pregnant, breastfeeding and not using medically acceptable birth
             control

          -  Subjects considered as unsuitable based on medical judgement by investigators
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ki-Bae Seung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular center and Cardiology Division, Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ki-Bae Seung, MD, PhD</last_name>
    <phone>82-2-2258-1139</phone>
    <email>kbseung@catholic.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kiyuk Chang, MD, PhD</last_name>
    <phone>82-2-2258-1139</phone>
    <email>kiyuk@catholic.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Center and Cardiology Division, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seochogu</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Min Lim, MD</last_name>
      <phone>82-2-2258-1139</phone>
      <email>sungmin@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Ki-bae Seung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 9, 2013</lastchanged_date>
  <firstreceived_date>January 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul St. Mary's Hospital</investigator_affiliation>
    <investigator_full_name>Kiyuk Chang</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
